Brief: Eiger Biopharmaceuticals On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq
03/04/2024 21:48
April 3 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER BIOPHARMACEUTICALS: ON APRIL 2, RECEIVED NOTICE
FROM
NASDAQ THAT CO'S COMMON STOCK WILL BE DELISTED FROM NASDAQ
* EIGER BIOPHARMACEUTICALS INC: COMMON STOCK IS EXPECTED TO
BEGIN
TRADING ON OVER--COUNTER MARKET ON APRIL 11
* EIGER BIOPHARMACEUTICALS: ON OTC MARKET, COMMON STOCK ARE
EXPECTED TO TRADE UNDER SYMBOL EIGRQ
Source text for Eikon: ID:n0001193125-24-086059
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview